Alterity Therapeutics Limited (ATH) Fair Value & Analysis
Healthcare · AU · Market cap A$2.0M
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price +24.4% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.3500 – A$0.8000 · fair‑value band A$0.6600 – A$1.10 · the A$0.5600 price screens below the A$0.8800 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Alterity Therapeutics Limited (ATH) currently trades at A$0.5600, while our model-based Fair Value estimate is A$0.8800 — implying the stock looks roughly 57.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at A$6.6M. Revenue grew 74.6% year over year. It earns a return on equity of -47.0%. The balance sheet holds a net cash position of A$33.0M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Alterity Therapeutics Limited reported revenue of A$5.4M in FY2025 versus A$4.3M in FY2021, a compound +5.8%/yr. Reported net income was −A$12.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Alterity Therapeutics Limited (ATH) undervalued?
What is the fair value of ATH?
What is the quality score of ATH?
What is the revenue of Alterity Therapeutics Limited (ATH)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.